Exicure (NASDAQ:XCUR) Shares Up 1.2% – Time to Buy?

Exicure, Inc. (NASDAQ:XCUR)’s share price shot up 1.2% on Wednesday . The company traded as high as $6.20 and last traded at $6.00. 50,315 shares were traded during trading, a decline of 8% from the average session volume of 54,673 shares. The stock had previously closed at $5.93.

Analyst Ratings Changes

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Exicure in a research report on Monday, December 29th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Exicure currently has a consensus rating of “Sell”.

Exicure Stock Up 1.2%

The stock’s 50 day moving average is $5.18 and its 200-day moving average is $5.48. The company has a market cap of $38.22 million, a PE ratio of -1.62 and a beta of 4.06.

Exicure (NASDAQ:XCUR) last posted its earnings results on Friday, November 7th. The company reported ($0.39) earnings per share for the quarter.

Insider Transactions at Exicure

In other Exicure news, major shareholder Sangsangin Investment & Securi sold 433,332 shares of the company’s stock in a transaction that occurred on Monday, December 8th. The stock was sold at an average price of $8.71, for a total transaction of $3,774,321.72. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 52.80% of the stock is currently owned by company insiders.

Exicure Company Profile

Exicure is a clinical‐stage biotechnology company pioneering the development of next‐generation genetic medicines through its proprietary spherical nucleic acid (SNA) delivery platform. This nanotechnology‐based approach is designed to facilitate the intracellular delivery of oligonucleotide therapeutics, addressing longstanding challenges in targeting hard‐to‐reach tissues such as the central nervous system.

The company’s pipeline encompasses programs for neurological disorders—including Huntington’s disease, Parkinson’s disease and Alzheimer’s disease—as well as exploratory efforts in dermatological indications and oncology.